N/A N=171 Psoriatic Arthritis Research Collaborative: Biologic Sub-Study
Psoriatic Arthritis
Primary: Patient Function Response to Biologic Therapy as Measured by RAPID3 — -1.11 change in score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
Primary Open-angle Glaucoma
Primary: Safety: Number of Patients Experiencing a Device Related Serious Adverse Events (SADE) and Device Related Adverse Events (ADE) — 0; 0 Participants
N/A N=110 Cognition and Psychotherapy in PTSD
Posttraumatic Stress Disorder (PTSD)
Primary: Change in PTSD Checklist (PCL-5) — 9.25; 11.94; 15.91 change in units on a scale
Phase 2 N=42 Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine
Alcohol Use Disorder
Primary: Completion Rates — 17; 18 Participants
N/A N=299 Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)
Follicular Lymphoma
Primary: Percentage of Participants With Progression of Disease at Year 2 (POD24) — 8.9 percentage of participants
N/A N=111 FitEx for Endometrial Cancer Survivors: Initial Efficacy
Endometrial Cancer · Obesity · Sedentary Behavior
Primary: Moderate to Vigorous Physical Activity of Endometrial Cancer Survivors — 3.7; 12.14; 3.15 minutes per day of MVPA
Phase 2 N=70 Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
MacTel (Macular Telangiectasia) Type 2
Primary: Ellipsoid Zone (Area of IS/OS Loss) - Cohort 1 — 0.697; 0.629; 1.37; 1.137 mm2
Phase 2 N=55 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Squamous Cell Carcinoma of Head and Neck
Primary: Best Percentage Change in Tumour Size — -7.88; -12.93 Percentage change from baseline — p=0.7008
N/A N=78 Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
Neurogenic Bladder · Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Willingness to Repeat Procedure — 9.16; 9.34; 9.73; 9.67 units on a scale — p=0.57
Phase 2 N=168 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Primary: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis…
Phase 2 N=71 Imaging Tau in Alzheimer's Disease and Normal Aging
Alzheimer Disease
Primary: 18F-MK-6240 Binding — 1.41; 2.30 SUVr
N/A N=55 Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Phase 1 N=49 Study of Novel Antiretrovirals in Participants With HIV-1
HIV-1-infection
Primary: Substudies 01, 02 and 03: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical…
Phase 1 N=12 PET Study of Repeated ASN51 in Healthy Volunteers
Healthy
Primary: Mean Protein O-GlcNAcylation in Peripheral Blood Mononuclear Cells (PBMCs) — 100.0; 100.0; 219.33; 232.79 percentage of protein O-GlcNAcylation
N/A N=7,444 Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Healthy
Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77